meta charset="utf-8"> About Us
中文
菜单
  1. Home
  2. About Us
About Us
Company Overview

Affinity (Shanghai) Biopharmaceutical Co., Ltd. (“Affinity”) was founded in Zhangjiang, Shanghai in 2012. Dedicated to addressing the toxicity challenges of conventional chemotherapy and targeted therapies while focusing on unmet clinical needs in oncology, it is a China-rooted, globally oriented biopharmaceutical enterprise independently developing first-in-class novel anti-cancer drugs.

The Company owns its globally pioneered, proprietary Tumor Microenvironment-Activated (TMEA) technology platform, with strategic R&D layout across two core therapeutic pillars: XDC and IO. Its full-spectrum pipeline spans innovative chemotherapy through immunotherapy, establishing distinctive proprietary technical moat.

Legubicin (QHL-108), one of the Company’s core assets, is a globally first-in-class TMEA-ALDC drug. It has completed a pivotal, double-blind, head-to-head Phase II/III clinical trial for advanced soft tissue sarcoma. Compared with conventional doxorubicin, Legubicin substantially reduces cardiotoxicity and hematologic toxicity while significantly prolonging patient survival, and its clinical development across multiple tumor types is steadily advancing.

Driven by its founding mission to resolve systemic adverse effects of conventional chemotherapy and fill unmet clinical medical gaps, Affinity advances in-house R&D alongside global business collaboration. It accelerates the translation of innovative breakthroughs via product out-licensing and technology partnerships. Going forward, Affinity is poised to transform traditional treatment regimens and reshape the landscape of cancer therapy, bringing groundbreaking original innovations to benefit oncology patients worldwide.

Management team
The core team of Affinity boasts an international perspective and extensive drug development experience, with proven end-to-end expertise across molecular biology, enzymology, immunology, anti-tumor drug discovery and product commercialization, business operations, clinical research and regulatory affairs.
    • Bachelor of Medicine from Shanghai Jiao Tong University School of Medicine;
    • Ph.D. in Biomedical Sciences, University at Albany, State University of New York
    • Former Professor of Immunology at the Scripps Research Institute,USA; Founder of Affinity
    • Original inventor of the Tumor Microenvironment-Activated (TMEA) drug platform
    • Long-standing focus on research in tumor microenvironment, tumor immunology, and intelligent drug design
    • Deep expertise in protease research and oncology therapeutic drug development
    Dr. Liu Cheng
    Founder, Chief Executive Officer, Chief Medical Officer

  • Dr. Yuan Liu is the Chief Technology Officer of Affinity Biopharma. Before joining Affinity Biopharma, he conducted postdoctoral research and worked as a researcher at the Scripps Research Institute in the United States. Dr. Yuan Liu has worked in several companies including MabPrex and Fosun Pharma as protein drug development scientist. Dr. Yuan Liu has more than 20 years of experience in protein drug research and development.

    In 2012, the first tumor protease-activated antibody was designed and published (Molecular Pharmaceutics 2012, 9(1), pp 168-175). In 2015, the first tumor protease-activated bispecific antibody was designed and published (Molecular Pharmaceutics 2015 Jul 6; 12(7):2544-50). In 2014, Dr. Yuan Liu was awarded the title of “Shanghai Pujiang Talent”, and in 2015, he was awarded the title of “Zhangjiang Excellent Talent”. In 2018, he was awarded the title of "Shanghai Outstanding Academic/Technical Leader".

    Yuan Liu, Ph.D.
    Chief Technology Officer

  • Mr. Chris Huang serves as Joint Chief Medical Officer at Affinity.
    Prior to joining the Company, he held senior roles across a roster of leading domestic and global pharmaceutical enterprises, including WuXi AppTec, AstraZeneca, PharmaNet and Bayer Pharmaceuticals.
    Mr. Huang brings 30 years of extensive experience in international new drug clinical development and clinical operation management.
    He holds medical degrees from the Department of Clinical Medicine, Shanghai Jiao Tong University School of Medicine, and the School of Pathology, Faculty of Medicine, University of New South Wales, Australia.


    Chris Huang
    Joint Chief Medical Officer

  • Mr. Yang is the Chief Financial Officer and Secretary to the Board of Directors of Yafei Biopharma, with extensive experience in finance, compliance, and healthcare industry management. Prior to joining the company, he held positions at KPMG, Novartis, and Shuangquan Holdings, among other renowned enterprises. He later served as CFO, Director and Board Secretary of Asieris (688176), and was appointed as a Non-Executive Independent Director (designate) of Puxiang Healthcare.

    Mr. Yang graduated from the School of Management, Fudan University, with a Bachelor’s degree in Accounting, and holds a Master of Business Administration (MBA) from the Antai College of Economics and Management, Shanghai Jiao Tong University.

    He is a holder of the Chinese Certified Public Accountant (non-practicing), FRM, and CFA qualifications.

    Mingyuan Yang
    Chief Financial Officer and Board Secretary
Affinity (Shanghai) Biopharmaceutical Co., Ltd.

Email: admin@affinity.net.cn

R&D and Business Development Cooperation: bd@affinity.net.cn

PR ：pr@affinity.net.cn

Address: 3rd Floor, Building 1, No. 368 Zhangjiang Road, Pudong New Area, Shanghai, China